Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Ms. Andrea Paul J.D. | Chief Legal Officer & Corporate Secretary | 682.47k | -- | 1982 |
| Ms. Julie M. Eastland M.B.A. | CEO, President & Director | -- | -- | 1964 |
| Mr. Vincent A. Vultaggio | SVP of Finance & Principal Accounting Officer | -- | -- | 1984 |
| Dr. Mark Lackner Ph.D. | Chief Scientific Officer | -- | -- | 1968 |
| Ms. Wendy Chang | Chief People Officer | -- | -- | -- |
| Ms. Kimberly Freeman | Chief Strategy Officer | -- | -- | -- |
| Dr. Ingmar Bruns M.D., Ph.D. | Chief Medical Officer | -- | -- | 1976 |
| Mr. Haibo Wang | Chief Business Officer | -- | -- | -- |
Zentalis Pharmaceuticals, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 166
Description
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.
Corporate Governance
Upcoming Events
May 5, 2025 at 12:30 PM UTC - May 9, 2025 at 12:30 PM UTC
Zentalis Pharmaceuticals, Inc. Earnings Date
Recent Events
October 10, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission